Core Viewpoint - The Yantai Yuhuangding Hospital is pioneering the use of Aβ-PET molecular imaging technology and targeted therapy for Alzheimer's disease (AD), enhancing diagnostic accuracy and treatment efficacy, thereby providing new hope for early-stage patients suffering from memory decline [2][4][9]. Group 1: Aβ-PET Technology and Its Impact - The introduction of Aβ-PET technology marks a significant advancement in AD diagnosis, transitioning from clinical symptom assessment to biomarker confirmation, which is essential for targeted treatment [4][5]. - Aβ-PET has successfully provided definitive diagnostic evidence for over 60% of clinically suspected patients, while nearly 40% of Aβ-negative patients were redirected to appropriate treatments, avoiding ineffective medication and financial loss [5][9]. Group 2: Targeted Therapy with Lecanemab - The first patient treated with lecanemab, a targeted therapy, demonstrated positive outcomes, confirming the hospital's capability to provide etiology-targeted treatment for early AD patients [7]. - The treatment process involved a multidisciplinary collaboration, ensuring comprehensive evaluation and monitoring, with no adverse reactions reported during the initial infusion [7]. Group 3: Value-Based Healthcare Approach - The hospital's approach exemplifies the "value-based healthcare" model, ensuring that innovative therapies are utilized effectively for patients most likely to benefit, thereby maximizing healthcare resource value [9]. - The cognitive impairment treatment team aims to optimize the diagnostic pathway and implement a dual-core screening model advocated by the National Health Commission, facilitating early detection and intervention for potential patients [9]. Group 4: Comprehensive Management Ecosystem - The hospital is developing a comprehensive management ecosystem for AD, integrating early screening, precise diagnosis, individualized treatment, long-term follow-up, family care guidance, and community rehabilitation support [9]. - This initiative aims to provide a "one-stop" health service throughout the patient's journey, contributing to the fight against Alzheimer's disease [9].